<DOC>
	<DOCNO>NCT02606032</DOCNO>
	<brief_summary>The investigator test hypothesis give antibiotic prior fecal transplant therapy active UC increase proportion patient remission end treatment . The investigator randomize patient age 18 active UC antibiotic ( metronidazole 500mg , doxycycline 100mg , Terbinafine 250 mg , twice daily two week ) ; identical placebo . At end two week investigator give patient fecal transplant therapy twice per week eight week donor whose stool show efficacy trial ( donor B ) . Patients complete validate UC questionnaire , flexible sigmoidoscopy ass degree inflammation colon complete general disease specific quality life questionnaire well questionnaire anxiety depression . Patients complete questionnaire end treatment week 9 also repeat flexible sigmoidoscopy . The main outcome assess proportion patient remission UC end treatment .</brief_summary>
	<brief_title>Trial Antimicrobials Versus Placebo Addition Fecal Transplant Therapy Ulcerative Colitis</brief_title>
	<detailed_description>Patients age 18 active UC define Mayo score &gt; 3 endoscopic score &gt; 0 eligible study . Subjects exclude participate another clinical trial , unable give inform consent , severe comorbid medical illness , concomitant Clostridium difficile infection severe UC require hospitalization . Continued treatment 5-ASA , azathioprine , 6-mercaptopurine anti-TNFα therapy ( e.g . infliximab ) permit take stable dose ≥12 week prior randomization . Eligible patient randomize 1:1 metronidazole 500mg bid , doxycycline 100mg bid , Terbinafine 250 mg identical placebo two week . Patients receive first FMT 1-3 day complete course antibiotic/placebo . The investigator also use stool donor B exclusively frozen/thawed FMT donor associate success previous trial administer St Joseph 's Hospital care Dr Lee . FMT administer twice per week 8 week . Eighty active UC patient randomize 1:1 accord computer generate randomization list . Randomization administer centrally GI Clinical Trials Unit ensure concealment allocation . Subjects sigmoidoscopy ( colonoscopy clinically indicate ) , physician assessment complete Mayo score , IBDQ questionnaire , EQ5D HAD questionnaires baseline . A repeat sigmoidoscopy , Mayo score , IBDQ , EQ5D HAD questionnaire complete 9 week , exit study ( one week last FMT ) . No new medical therapy ( e.g . corticosteroid , antibiotic , probiotic ) permit 9 week study period .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Patients age 18 2 . Active UC define Mayo score &gt; 3 3 . A Mayo endoscopic score &gt; 0 1 . Participating another clinical trial 2 . Unable give inform consent 3 . Severe comorbid medical illness 4 . Concomitant Clostridium difficile infection 5 . Severe UC require hospitalization . 6 . Increase medical therapy UC last 12 week . Continued treatment 5ASA , azathioprine , 6mercaptopurine antiTNF alpha therapy ( e.g . infliximab ) permit take stable dose ≥12 week prior randomization . Relapse stable dose ( dose least 2 week ) taper dose steroid also permit provide dose steroid increase . Stable intake probiotic therapy also permit . 7 . Antibiotic therapy last 30 day . 8 . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Fecal Microbiota Transplant</keyword>
	<keyword>Antibiotics</keyword>
</DOC>